Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery
Open Access
- 16 February 2021
- journal article
- research article
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 10 (4), e12057
- https://doi.org/10.1002/jev2.12057
Abstract
Natural extracellular vesicles (EVs) are ideal drug carriers due to their remarkable biocompatibility. Their delivery specificity can be achieved by the conjugation of targeting ligands. However, existing methods to engineer target‐specific EVs are tedious or inefficient, having to compromise between harsh chemical treatments and transient interactions. Here, we describe a novel method for the covalent conjugation of EVs with high copy numbers of targeting moieties using protein ligases. Conjugation of EVs with either an epidermal growth factor receptor (EGFR)‐targeting peptide or anti‐EGFR nanobody facilitates their accumulation in EGFR‐positive cancer cells, both in vitro and in vivo. Systemic delivery of paclitaxel by EGFR‐targeting EVs at a low dose significantly increases drug efficacy in a xenografted mouse model of EGFR‐positive lung cancer. The method is also applicable to the conjugation of EVs with peptides and nanobodies targeting other receptors, such as HER2 and SIRP alpha, and the conjugated EVs can deliver RNA in addition to small molecules, supporting the versatile application of EVs in cancer therapies. This simple, yet efficient and versatile method for the stable surface modification of EVs bypasses the need for genetic and chemical modifications, thus facilitating safe and specific delivery of therapeutic payloads to target cells.This publication has 38 references indexed in Scilit:
- Extracellular vesicles: biology and emerging therapeutic opportunitiesNature Reviews Drug Discovery, 2013
- Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of NanoparticlesScience, 2013
- Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer CellsMolecular Therapy, 2013
- A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growthInternational Journal of Cancer, 2011
- Delivery of siRNA to the mouse brain by systemic injection of targeted exosomesNature Biotechnology, 2011
- Tumour microvesicles contain retrotransposon elements and amplified oncogene sequencesNature Communications, 2011
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Sortagging: a versatile method for protein labelingNature Chemical Biology, 2007
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeuticsThe FASEB Journal, 2005